Partner Profile

Sanofi Pasteur, the vaccine division of Sanofi is the largest company in the world devoted entirely to human vaccines. Sanofi Pasteur distributes more than 1 billion doses of vaccine per year, making it possible to vaccinate more than 500 million people across the globe.

Pharmacoepidemiology and Risk management unit in the Global Pharmacovigilance department is leading design and conduct of observational post-authorization safety studies, Pharmacovigilance risk management activities, including support of safety signal evaluation. *The Global Epidemiology Department* leads design and conducts of observational studies related to burden of disease and natural history, as well as post-licensure evaluations of vaccine effectiveness and impact.

Websites: www.sanofipasteur.com; www.youtube.com/SanofipasteurTV

Role in the ADVANCE Project

Sanofi Pasteur is co-leader of WP3 (data sources for rapid and integrated benefit-risk monitoring) and will also contribute to WP4 (methods) and WP5 (proof of concept studies).

Key People

Alena Khromava, Head of Pharmacoepidemiology and Risk Management team at Sanofi Pasteur, received her MD degree from Gomel State Medical University, Belarus (1998), MPH degree from Emory University in Atlanta, GA, USA (2000). From 2000 to 2002 Alena has worked as a medical epidemiologist on multi-drug resistant tuberculosis, STDs and HIV in Moscow, Russia. Alena completed Epidemiology Intelligence Service training at the US Centers for Disease Control and Prevention in Immunization Safety Branch (2002-2004). Alena is a co-leader of WP3 (data sources) and a member of the ADVANCE steering committee

Michael Greenberg, Head of Global Epidemiology at Sanofi Pasteur, received his MD from the Medical College of Georgia (1992) and MPH from the University of California, Berkeley in 2001. Board certified in Pediatrics and Preventive Medicine, Michael practiced pediatrics in the San Francisco Bay Area before moving progressively to work in public health. He served as an Epidemic Intelligence Service (EIS) officer at the US Centers for Disease

Control and Prevention working on STDs and influenza. He subsequently joined GSK Biologicals in Belgium as an epidemiologist, CSL in Australia heading vaccine clinical development, and now at Sanofi Pasteur since 2011. Michael is a member of the ADVANCE steering committee.

Catherine Panozzo, Deputy Director of Pharmacoepidemiology and Risk Management at Sanofi Pasteur, received her MPH in epidemiology of microbial diseases from Yale University in 2006 and then worked at the US Centers for Disease Control and Prevention in Atlanta from 2006 to 2009. She started working at Sanofi Pasteur in 2012 and finished her PhD in epidemiology from the University of North Carolina at Chapel Hill in 2013. She participates in the WP4 (methods).



Caroline Legendre, Pharmacoepidemiologist at Sanofi Pasteur, received her master in public health vigilance from Lyon University (France) in 2006 and then worked as safety officer at SP from 2006 to 2010. She received her master of pharmacovigilance and pharmacoepidemiology from Bordeaux University (France) in 2008 and evolved to a pharmacoepidemiologist position in 2010. She participates in WP5 (proof of concept studies).

Christine Luxemburger, Senior Director Epidemiology at Sanofi Pasteur, received her MD from the Faculty of Medicine of Lyon, France (1988) and PhD from the London School of Hygiene and Tropical Medicine, UK in 1999. She started her professional career as a general practitioner in France before joining Médecins Sans Frontières (MSF). She moved to public health and worked in Thailand and Vietnam for 10 years as clinical epidemiologist on malaria and dengue in a community-based research unit from the Wellcome Trust Mahidol-Oxford Tropical Medicine Research Programme. She joined Sanofi Pasteur in 2000. She participates in WP5 (proof of concept study)

Bertrand Borie, Deputy Director Regulatory Policy and Intelligence at Sanofi Pasteur, studied Biology at Paris XII University. He started his career at SP in 1989 within the Quality Control Department. He holds more than 20 years experience in the regulatory field both at international and European level.